BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/17/2022 3:19:27 AM | Browse: 298 | Download: 540
 |
Received |
|
2022-02-06 21:40 |
|
Peer-Review Started |
|
2022-02-06 21:42 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-03-23 09:01 |
|
Revised |
|
2022-04-01 00:20 |
|
Second Decision |
|
2022-05-11 03:02 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-05-12 20:15 |
|
Articles in Press |
|
2022-05-12 20:15 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-05-09 21:24 |
|
Typeset the Manuscript |
|
2022-06-01 13:42 |
|
Publish the Manuscript Online |
|
2022-06-17 03:19 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Stem cells as an option for the treatment of COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maria Veronica Cuevas-González and Juan Carlos Cuevas-González |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Juan Carlos Cuevas-González, PhD, Academic Research, Institute of Biomedical Sciences, Autonomous University of Ciudad Juárez, Av. Benjamín Franklin No. 4650, Zona Pronaf Condominio La Plata, Ciudad Juarez 32310, Chihuahua, Mexico. cuevas_gonzalez@hotmail.com |
| Key Words |
COVID-19; Stem cells; Multiple diseases; Undifferentiated cells; Appropriate treatment; Cytokines granulocyte-macrophage colony-stimulating factor |
| Core Tip |
The stem-cell-derived microvesicles improve the oxygenation conditions of patients, thereby avoiding mechanical oxygenation methods. They demonstrate the ability to modulate the inflammatory response by reducing the levels of proinflammatory cytokines within the first few hours of their intravenous application, because these microvesicles contain cytokines, growth factors, and microRNAs, which function as anti-inflammatory agents. |
| Publish Date |
2022-06-17 03:19 |
| Citation |
Cuevas-González MV, Cuevas-González JC. Stem cells as an option for the treatment of COVID-19. World J Clin Cases 2022; 10(18): 6338-6340 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i18/6338.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i18.6338 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
